This study is advantaged at the identification and validation of a novel 2-TF signature consisted of HMGA1 and MAFG, which is able to predict the prognosis and therapeutic response of HCC via distinguishing the characteristics of tumor proliferation and metabolism. The gene discussed is HMGA1; the disease is hepatocellular carcinoma.